CorMedix gains FDA approval for DefenCath

16 November 2023
fda_food_and_drug_administration_large

Shares of US biopharma CorMedix (Nasdaq: CRMD) rose as much as 18% ad closed up 6.4% at $3.33 yesterday, after it revealed that the US Food and Drug Administration (FDA) has approved its DefenCath (taurolidine and heparin).

DefenCath is a catheter lock solution (CLS) and has been authorized to reduce the incidence of catheter-related bloodstream infections (CRBSIs) for the limited population of adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC).

The company noted that DefenCath is the first and only FDA-approved antimicrobial CLS in the USA and was shown to reduce the risk of CRBSIs by up to 71% in a Phase III clinical study.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical